Skip to main content

    MSF: Governments off track on providing tools to prevent TB, the second biggest infectious disease killer after COVID-19

    Everybody Breathes: Treating TB in Eshowe, South Africa

    Everybody Breathes is a package documenting how the lessons learnt from the initial phases of the ‘Bending The Curves’ initiative in South Africa are now being used by MSF in Eshowe to tackle TB. The package will document interventions the project is putting in place in collaboration with its partners to prevent the spread of TB, provide a link for patients to get tested, locate missing cases and ensuring patients remain on treatment with structures that fit into their lives. © Tadeu Andre/MSF 

    TB was only recently surpassed by COVID-19 as the world’s number one infectious disease killer. In 2019, TB claimed the lives of 1.4 million people and more than 10 million people fell ill. While treating people who are currently sick with TB is essential, another important measure to control and reverse the tide of the global TB burden is to promptly identify people at risk and prevent them from developing the disease through preventive treatment or TPT. TPT involves providing anti-TB drugs to family members and other close contacts of people sick with TB, to people with HIV or other conditions that weaken their immune system or to people otherwise at-risk, including people who are incarcerated. This preventive treatment will prevent people with latent TB (someone infected with TB, but not yet sick, contagious or showing symptoms) from developing full blown TB that could ultimately not only make them seriously ill, but also infect others. Scale-up of TPT is even more critical in the context of COVID-19. Urgent action is required to reverse the negative impact of COVID-19 on TB control.

    In 2018, countries agreed during the United Nations High-Level Meeting on TB to meet the target of 30 million people started on TPT by the end of 2022. However, even though the effectiveness of TPT has been repeatedly demonstrated, progress is lagging behind. With only 18 months left, governments must urgently prioritise and scale up the implementation of preventive TB treatment to save more lives and alleviate suffering.

    “It’s unacceptable that millions of lives continue to be taken by TB when preventive measures exist. There’s no light at the end of the TB tunnel without a massive scale-up in preventive treatment for TB,” said Dr Gabriella Ferlazzo, Senior TB/HIV Advisor at MSF’s Southern Africa Medical Unit. “Governments must urgently step up and fulfil their commitments and invest in TB preventive action so that everyone in need, including children and particularly vulnerable populations like people with HIV, people who are incarcerated or refugees, can access TB preventive treatment. We must strengthen our efforts to identify and provide TB preventive treatment to around three contacts for every person diagnosed with TB, so that we can close this prevention gap, prevent infection and transmission, and save more lives.”

    MSF aims to provide TPT as an integral part of the organisation’s comprehensive TB response. In Blantyre, Malawi, MSF supported a TB programme in the Chichiri prison. As people who are incarcerated – especially in high HIV- and TB-burden settings – are at a very high risk of being infected and developing TB, the programme screened for and treated people with TB, and provided TPT for people with latent TB infection and for people living with HIV. In 2019, the programme screened 1,500 people, and nearly two-thirds of those screened were started on TPT (666 HIV negative individuals and 324 people with HIV).

    In Khayelitsha, South Africa, MSF has successfully provided TPT for children and adolescents who are contacts of people with drug-resistant TB (DR-TB). The COVID-19 pandemic required MSF to adapt its programme to start providing home-based care, which ultimately led to an increase in children and adolescents started on TPT through this community-based initiative.

    “DR-TB is a serious problem in Khayelitsha, a never-ending cycle that ravages family after family,” said Sister Ivy Apolisi, DR-TB nurse for MSF’s DR-TB post-exposure programme in Khayelitsha, South Africa, and one of the speakers at WHO’s event on Wednesday. “But we’ve seen how TB preventive treatment saves lives, and, as a nurse, I can tell you how much better and easier it is to prevent TB, rather than watching and waiting to see if someone gets sick. We must all dedicate ourselves to stopping the ongoing cycles of suffering that occur in families affected by DR-TB.”

    TPT implementation is lagging in part due to a lack of access to the best tests and drugs. Most people only have access to the older TPT drug (isoniazid) that requires taking pills for 6-9 months. But a newer and shorter 1- to 3-month preventive treatment (rifapentine + isoniazid) exists, although it is more expensive (US$5 to $26.90 per month for the 3- and 1-month regimens respectively, versus $0.58 per month for the older single isoniazid-based

    regimen). In addition, quality-assured rifapentine is only produced by two manufacturers (Sanofi and Macleods) because of limited demand, despite the fact that rifapentine has been off-patent for years, and it is not available in a child-friendly formulation. Further research into innovative alternatives that would make TPT easier, including long-acting injectable formulations of TPT drugs, would encourage greater scale-up.

    Access to the diagnostic tools needed to screen widely for TB is also critical to ensure that healthcare workers provide TPT to the right people. More affordable and simpler point-of-care tests adapted to low-resource settings to identify people with latent TB are urgently needed to accelerate TPT implementation.

    "To achieve a sustained and affordable supply of rifapentine and isoniazid from manufacturers, countries must commit to purchasing sufficient volumes of the drugs. Considering that rifapentine and isoniazid are off patent, commitment to purchasing certain volumes would ensure more manufacturers would enter the market and lead to price-lowering competition and scale-up,” said Christophe Perrin, TB Advocacy Pharmacist for MSF’s Access Campaign. “All countries should be held accountable when it comes to scaling up and rapidly implementing TB preventive treatment, but to do so they require access to the best drugs and diagnostic tests at affordable prices."